Literature DB >> 33437366

SCAMP3 is regulated by miR-128-3p and promotes the metastasis of hepatocellular carcinoma cells through EGFR-MAPK p38 signaling pathway.

Le Kang1, Ze-Hua Zhang1,2, Ying Zhao3.   

Abstract

PURPOSE: To explore the regulatory mechanism of secretory carrier membrane protein 3 (SCAMP3) and miR-128-3p in hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Cancer tissues and adjacent tissues of 52 HCC patients treated in our hospital were collected to explore the prognostic factors affecting their 3-year survival. HCC cells were purchased, the gene expression of Huh-7 and MHCC97 were adjusted by transfection, and the levels of SCAMP3, miR-128-3p, EGFR, p-EGFR, MAPK p38, p-MAPK p38, N-cadherin, vimentin, E-cadherin, cell proliferation, migration, invasion, apoptosis and epithelial-mesenchymal transition (EMT) were detected. A nude mouse model of HCC was constructed to verify the effects of transfection of mimics.
RESULTS: SCAMP3 was elevated in HCC patients and cancer tissues of HCC patients, while miR-128-3p showed opposite effects. High level SCAMP3 and low level miR-128-3p were related to poor prognosis of HCC. Both of them were correlated with excessive drinking history, N-stage, M-stage and pathological differentiation degree of HCC patients, as well as prognostic factors of HCC patients. SCAMP3 up-regulation or miR-128-3p down-regulation could promote HCC cell proliferation, migration, invasion, and transcription and protein levels of EGFR, p-EGFR, MAPK p38, p-MAPK p38, N-cadherin and vimentin, and inhibit HCC cell apoptosis and transcription and protein levels of E-cadherin. Dual luciferase reporter identified the targeting relationship between SCAMP3 and miR-128-3p. When both SCAMP3 and miR-128-3p were elevated or reduced, the biological manifestation of cells was not different from that of miR-NC transfected with unrelated sequences. Besides, miR-128-3p inhibited tumor growth in the HCC model in nude mice.
CONCLUSION: SCAMP3 can be controlled by miR-128-3p and can mediate the EGFR-MAPK p38 signaling pathway to inhibit HCC cell metastasis, which is expected to become a promising therapeutic target for HCC. AJTR
Copyright © 2020.

Entities:  

Keywords:  EGFR-MAPK p38; SCAMP3; hepatocellular carcinoma; metastasis; miR-128-3p

Year:  2020        PMID: 33437366      PMCID: PMC7791489     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  28 in total

1.  Polycyclic aromatic hydrocarbons induce migration in human hepatocellular carcinoma cells (HepG2) through reactive oxygen species-mediated p38 MAPK signal transduction.

Authors:  Mi-Kyung Song; Youn-Jung Kim; Mee Song; Han-Seam Choi; Yong-Keun Park; Jae-Chun Ryu
Journal:  Cancer Sci       Date:  2011-07-08       Impact factor: 6.716

Review 2.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

Review 3.  Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines.

Authors:  Carmen Ayuso; Jordi Rimola; Ramón Vilana; Marta Burrel; Anna Darnell; Ángeles García-Criado; Luis Bianchi; Ernest Belmonte; Carla Caparroz; Marta Barrufet; Jordi Bruix; Concepción Brú
Journal:  Eur J Radiol       Date:  2018-01-31       Impact factor: 3.528

Review 4.  Viral hepatitis and hepatocellular carcinoma: etiology and management.

Authors:  Philippe J Zamor; Andrew S deLemos; Mark W Russo
Journal:  J Gastrointest Oncol       Date:  2017-04

5.  miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients.

Authors:  Chao-Yuan Huang; Xin-Ping Huang; Ji-Ye Zhu; Zhi-Gang Chen; Xian-Jian Li; Xue-Hui Zhang; Shan Huang; Jian-Bo He; Fang Lian; Yin-Nong Zhao; Guo-Bin Wu
Journal:  Oncol Rep       Date:  2015-04-28       Impact factor: 3.906

Review 6.  The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.

Authors:  Carmen Berasain; Matías A Avila
Journal:  J Gastroenterol       Date:  2013-12-10       Impact factor: 7.527

Review 7.  Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.

Authors:  Valery Vilchez; Lilia Turcios; Francesc Marti; Roberto Gedaly
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

8.  Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.

Authors:  Dianke Yu; Bridgett Green; April Marrone; Yongli Guo; Susan Kadlubar; Dongxin Lin; James Fuscoe; Igor Pogribny; Baitang Ning
Journal:  Sci Rep       Date:  2015-02-23       Impact factor: 4.379

Review 9.  Hepatocellular carcinoma: a review.

Authors:  Julius Balogh; David Victor; Emad H Asham; Sherilyn Gordon Burroughs; Maha Boktour; Ashish Saharia; Xian Li; R Mark Ghobrial; Howard P Monsour
Journal:  J Hepatocell Carcinoma       Date:  2016-10-05

10.  Effects of UPF1 expression on EMT process by targeting E‑cadherin, N‑cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line.

Authors:  Yawei Li; Tiantian Zhang; Shukui Qin; Rui Wang; Yumei Li; Zhengguang Zhou; Yufo Chen; Qiong Wu; Fang Su
Journal:  Mol Med Rep       Date:  2019-01-10       Impact factor: 2.952

View more
  4 in total

1.  T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.

Authors:  Xiaoyu Ji; Xiaoping Chen; Bixiang Zhang; Meng Xie; Tongyue Zhang; Xiangyuan Luo; Danfei Liu; Yangyang Feng; Yijun Wang; Mengyu Sun; Congxin Li; Wenjie Huang; Limin Xia
Journal:  Oncogene       Date:  2022-02-26       Impact factor: 9.867

2.  The promising role and prognostic value of miR-198 in human diseases.

Authors:  Xiaoping Wang; Yanxia Zhu; Qiuli Xie
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

3.  Functional mechanism of hsa-miR-128-3p in epithelial-mesenchymal transition of pancreatic cancer cells via ZEB1 regulation.

Authors:  Tianying Zheng; Wenfei Han; Aijun Wang; Yonggang Wang
Journal:  PeerJ       Date:  2022-02-03       Impact factor: 2.984

4.  Investigation of Anti-Liver Cancer Activity of the Herbal Drug FDY003 Using Network Pharmacology.

Authors:  Ho-Sung Lee; In-Hee Lee; Sang-In Park; Minho Jung; Seung Gu Yang; Tae-Wook Kwon; Dae-Yeon Lee
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-09       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.